Steven Kok Hing Foung

Title: The Innovations of Steven Kok Hing Foung

Introduction

Steven Kok Hing Foung is an accomplished inventor based in Stanford, CA. He is known for his significant contributions to the field of biotechnology, particularly in the development of proteins and antibodies related to human T-cell lymphotropic viruses.

Latest Patents

Foung holds a patent for the "Human T-cell lymphotropic virus type II envelope protein and human monoclonal antibodies specific therefor." This patent describes an isolated and purified envelope protein of HTLV-I, which is devoid of non-envelope proteins and maintains a conformation similar to that of the native HTLV-I envelope protein. The protein is produced recombinantly using a dual vaccinia/T7 polymerase system. Both non-glycosylated and glycosylated forms of the protein are produced, with the glycosylated forms being recognized by antibodies specific for the HTLV-I envelope protein. Additionally, monoclonal antibodies specific for the HTLV-I envelope protein are provided, which do not bind to the denatured form of the protein. The HTLV-I envelope protein is cross-reactive with antibodies of HTLV-II and STLV, making it useful in diagnosing infections caused by HTLV-I and HTLV-II. He has 1 patent to his name.

Career Highlights

Foung's career has been marked by his innovative research and development in the field of virology and immunology. His work has contributed to a better understanding of human T-cell lymphotropic viruses and their implications for human health.

Collaborations

Some of his notable coworkers include Gregory A Dekaban and Jacqueline Arp, who have collaborated with him on various research projects.

Conclusion

Steven Kok Hing Foung's contributions to biotechnology and his innovative patent on HTLV-I envelope proteins highlight his role as a significant inventor in the field. His work continues to impact the diagnosis and understanding of viral infections.